Only available in German

Only available in German

Only available in German

The opportunities of stem cell and other cell-based therapies raise great hopes in physicians as well as patients. Due to novel therapies, major progress is expected particularly in the areas of difficult-to-treat, chronic and incurable diseases. In order to prevent illegal profiteering, it is important for authorities to monitor this quickly evolving therapeutic area.

The marketing authorisation holder informed its customers on April 4, 2019 that there is a risk that "Parkemed - Suspension zur oralen Anwendung" will likely contain levels of Lead (Pb) and Lithium (Li) which exceed the Permitted Daily Exposure (PDE) levels.

The marketing authorisation holder and its distribution partner informed their customers on March 25, 2019 that particles had been detected in individual batches.

The marketing authorisation holder informed its customers on March 6, 2019 that the marketing of „Tetraspan 60 mg/ml Infusionslösung“ and „Venofundin 60 mg/ml Infusionslösung“ is ceased permanently for economic reasons.

The marketing authorisation holder informed its customers on February 19, 2019 that the marketing authorisation of „Vantobra 170 mg Lösung für einen Vernebler“ will be withdrawn.

For more information on this topic, follow the link to the security features .

The parallel distributor „HAEMATO PHARM GmbH“ informed its customers on February 14, 2019 that the supply chain is not fully documented and GDP-guidelines are not met.